|
|
 All of the active B12 group reporting showed reduction in severity of symptoms ranging from 31% to 70%, while the placebo controls reported either no change or a worsening of symptoms. Wilcoxon-Rank of .002 for the end-points of sneezing, nasal congestion and runny nose; and p = .005 for IgE reductions. In 1992, the above mentioned data from 1988 on were presented by Dr. O''Connor to the FDA. The FDA panel acknowledged the safety myomaxmeal and myomaxmeal of the treatment. The panel seemed to be in agreement that the statistics indicated a significant reduction in IgE and that a quantitative drop in symptoms was demonstrated. In 1992, Belen Anibarro, MD, studied five children with asthma with metabisulfite intolerance confirmed by myomaxmeal oral challenge testing. The test was repeated after premedication with 1.5 mg of oral cyanocobalamin. In four of the five patients treated, bronchospasm did not develop in the second metabisulfite challenge.6 A recent study in Japan indicates that B12 treatment helps in the growth and division of certain immune system cells.11 myomaxmeal These myomaxmeal cells function to prevent the immune system from over-reacting to allergens such as animals, mold, dust, and pollen. They are called suppressor cells or CD8+ lymphocytes. They “put the brakes on the immune system”. this medicationTM is a 21-day treatment of B12 lozenges sucked on twice daily. this medicationTM myomaxmeal may help patients with hay fever by providing the patient’s suppressor cells with the sustained and elevated blood B12 level they need to grow and divide. It appears that by helping the immune system to become what it is genetically capable of becoming, this medicationTM turns at least some allergic people into non-allergic or moderately-allergic people. With no further treatment, the 1996 ten-month follow-up data (n=92) from a high pollen period in Oregon, Washington and Idaho together myomaxmeal showed a greater reduction in the active group (n=43) than the placebo group (n=49) on the primary endpoint, defined as a combination of symptom and rescue medication scores.8 Patients gave blood serum samples prior to the treatment in 1995 and one year later in 1996. They were immunoassayed for specific IgE antibodies using a chemi-luminescent technique. Statistician Bradley Rosebrook ran T-Tests comparing average baseline IgE levels to one-year. For the seasonal allergens reported, the active group (n=27) had on average a greater reduction in IgE than the placebo group (n=34) for 13 out of 16 allergens.8 If you are looking to loose weight but don't have time to do all those activities you must do to even loose a pound? Well do we have the fat burning supplements your looking for. Come in and check us out! Our site is very easily navigated.
|